We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New High Precision Kits Available for Gyros Immunoassay Platform

By LabMedica International staff writers
Posted on 31 Mar 2014
Print article
Caption: EMD Millipore's new high-precision GyroMark HT immunoassays of important biomarkers for use on the Gyros automated, high-throughput platform (Image courtesy of EMD Millipore and Gyros).
Caption: EMD Millipore's new high-precision GyroMark HT immunoassays of important biomarkers for use on the Gyros automated, high-throughput platform (Image courtesy of EMD Millipore and Gyros).
New ready-to-use kits designed for the Gyros high-throughput immunoassay platform will enable generation of high quality data for clinical research and drug development faster than typical ELISA kits.

EMD Millipore, life sciences division of Merck KGaA (Darmstadt, Germany) has released its initial set of "GyroMark HT" immunoassay kits, 5 new kits designed specifically for use on the "Gyrolab xP" workstation from Gyros AB (Uppsala, Sweden). Traditional ELISAs can consume significant time, sample, and reagents. With the automated, walk-away system from Gyros, up to 480 data points can be generated in a single run using less sample and reagents. The initial launch includes assays for important metabolic and toxicity biomarkers, such as GLP-1, insulin, clusterin, and KIM-1. EMD Millipore plans to release additional kits this year and offers custom kits for companies with specific needs or unique or novel antibodies.

The GyroMark HT kits are fully qualified for reliable use in clinical research and feature simple, automated, nanoliter-scale assays requiring as little as 1 µL of sample – with assay precision and accuracy that meet or exceed ELISA performance. “We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” said Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at EMD Millipore.

Employing microfluidic technology with parallel processing, the Gyros platform offers many advantages over traditional assays in addition to reagent and time savings. GyroMark HT assays further provide: accuracy over a four-log dynamic range (compared to two logs for ELISAs); elimination of cross-talk and plate position artifacts; and simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference.

Maria Hjortsmark, Gyros’ Global Marketing Director, commented, “Gyrolab system revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale, and using a fully automated system. We are delighted that EMD Millipore has now chosen to work with us to develop off-the-shelf kits to further reduce time-to-results, freeing up analyst time and offering an easier route to robust, reproducible data.”

Related Links:

Gyros
EMD Millipore


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.